Crucell has granted a license for its PER.C6 cell line technology
to Novavax, allowing the latter company to start offering contract
manufacturing services for vaccines.
The US market for media, sera and reagents used in cell culture is
expected to nearly double in value to reach $1.7 billion (€1.48bn)
in 2008, according to a report.
The market for cell culture products is getting a lift from
stringent regulations from the US FDA and Department of
Agriculture, restricting the importation and usage of foetal bovine
serum